Business: Bristol Myers-Squibb Acquires ZymoGenetics

Bristol Myers-Squibb completed its acquisition of Zymogenetics on October 12th, 2010, in a deal worth over $735 million. Shareholders will receive $9.75 per share. ZymoGenetics has now become a wholly-owned subsidiary of Bristol-Myers Squibb.

Bristol-Myers Squibb is a global biopharmaceutical company with sales of $18.8 billion in 2009. Zymogenetics develops novel protein drugs and raised $120 million through public offerings in 2002. The company is currently marketing a product called RECOTHROM which aids hemostasis, but also has other protein medications in development including treatments for Hepatitis C and metastatic melanoma.


In This Story: Bristol Myers-Squibb

Bristol Myers Squibb is an American multinational pharmaceutical company, headquartered in New York City. BMS is one of the world’s largest pharmaceutical companies, and is consistently ranked on the Fortune 500 list of the largest U.S. corporations. As of September 2020, it had total revenue of $39.3 billion.

Stock tickers: (NYSE: BMY, S&P 100 component, S&P 500 component)

3 Recent Items: Bristol Myers-Squibb

Leave a Comment

We don't require your email address, or your name, for anyone to leave a comment. If you do add an email address, you may be notified if there are replies to your comment - we won't use it for any other purpose. Please make respectful comments, which add value, and avoid personal attacks on others. Links are not allowed in comments - 99% of spam comments, attempt to post links. Please describe where people may find additional information - for example "visit the UN website" or "search Google for..." rather than posting a link. Comments failing to adhere to these guidelines will not be published.